About this trial

This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.

Eligibility criteria

Qualifiers

Pathology confirmed diagnosis of localized or locally advanced prostate cancer

Being able to speak, read and understand Dutch, French, or English

Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he understands the purpose of, and is willing to participate in the study.

Disqualifiers

Patients with prior treatment for prostate malignancies will be excluded.

Dementia, mental alteration, or psychiatric pathology that can compromise informed consent from the patient and/ or adherence to the protocol and the monitoring of the trial

Patients who cannot submit themselves to following the protocol for psychological reasons, social, family, or geographical.

Persons deprived of liberty or under guardianship

Trial design

Treatments tested in this trial

  • standard of care

Treatment groups

5,000 Participants
are divided into 1 treatment group

Locations

4
AZ Sint-Blasius9200, DendermondeOost-Vlaanderen, Belgium
University Hospitals Leuven3000, LeuvenVlaams-Brabant, Belgium
AZ Sint-Jan Brugge8000, BrugesWest-Vlaanderen, Belgium
AZ Groeninge Kortrijk8500, KortrijkWest-Vlaanderen, Belgium

Sponsors and collaborators

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

AZ Sint-Jan AV

Collaborator

General Hospital Groeninge

Collaborator

AZ Sint-Blasius Dendermonde

Collaborator